Antonio Jimeno, MD
Enriched profileProfessor of Medicine in Medical Oncology · University of Colorado Cancer Center
Antonio Jimeno is Professor of Medicine in Medical Oncology at University of Colorado Cancer Center. OpenAlex indexes 442 publications with 30,900 citations (h-index 66); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Antonio Jimeno, MD, is Professor of Medicine in Medical Oncology at University of Colorado Cancer Center, Anschutz Medical Campus. The public record shows 442 publications with 30,900 citations (h-index 66), centered on Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 1 companies, 10 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · Cancer research communications
- Top research focus: Head and Neck Cancer Studies
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 152.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Sponsor: Corbus Pharmaceuticals Inc.
- Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Sponsor: University of Colorado, Denver
Industry payments
Updated 18 Oct 2026
1 company reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
37.3%l-Thyroxine37.3%Levothyroxine Sodium100%Part D≥16 patientsMetabolism & gastrointestinal
31.7%Proton pump inhibitor16.1%Omeprazole100%Part D<11 patientsSerotonin-3 Receptor Antagonist15.5%Ondansetron Hcl100%Part D≥14 patientsSensory organs
17.4%Corticosteroid17.4%Dexamethasone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
10 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- Cell Immunotherapy and Experimental Therapeutics Program (CIETP).
University of Colorado Denver
FY2026$568,969T32CA236734 - Developing autologous organoid and humanized mouse models with thymic T cell education capacity to test head and neck cancer immunotherapy
University of Colorado Denver
FY2026$552,009R01DE036354 - Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer
University of Colorado Denver
FY2026$514,427R01CA149456
Congress activity
Updated 18 Oct 2026
54 congress contributions (2005–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- 1012P Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
ESMO Congress
ESMO2024Co-authorPoster
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes.
Cancer research communications
Article2026 - Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts.
Cancer research communications
Article2025
Most-cited works
by citation count (OpenAlex)- 01Oncogenic Signaling Pathways in The Cancer Genome AtlasArticle3,177 citations2018
- 02Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of CancerArticle2,529 citations2018
- 03Machine Learning Identifies Stemness Features Associated with Oncogenic DedifferentiationArticle2,174 citations2018
- 04
- 05Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyArticle1,360 citations2020
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
cancernetwork.com/authors/antonio-jimeno-md-phd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Mentions by others
where others cite or feature them- Other
medschool.cuanschutz.edu/colorado-cancer-center/research/membership-resources/Jimeno-Antonio-UCD10376
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.cuanschutz.edu ↗ - Other
profiles.ucdenver.edu/display/226120
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucdenver.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cumedicine.us ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cumedicine.us ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.cuanschutz.edu ↗
Secondary affiliations
appointments beyond the home institution- Department of Otolaryngology
University of Colorado Anschutz Medical Campus
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.cuanschutz.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.cuanschutz.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wells Messersmith, MD
University of Colorado Cancer Center
Manali Kamdar, MD
University of Colorado Cancer Center
Richard Schulick, MD, MBA
University of Colorado Cancer Center
Bryan Haugen, MD
University of Colorado Cancer Center
Neal Futran, MD
University of Washington (UW Medicine)
Everett Vokes, MD
University of Chicago
Maura Gillison, MD
The University of Texas MD Anderson Cancer Center
Christine Chung, MD
Moffitt Cancer Center